1349043-29-3

Upstream product

• 578-66-5 8-amino quinoline 
• 863036-65-1 (2E)-3-phenyl-N-[1-amino-2,2,2-trichloroethyl]-2-acrylamide 
• 1012883-18-9 8-(2,2,2-trichloroethoxyformylamino)quinoline 
• 1429483-83-9 C₁₂H₉Cl₃N₂O₂ 
• 863036-33-3 3-phenyl-N-(2,2,2-trichloro-1-isothiocyanato-ethyl)-acrylamide 
• 16535-67-4 (2E)-3-phenyl-N-[1-hydroxy-2,2,2-trichloroethyl]-2-acrylamide 
• 621-79-4 cinnamamide 
• 102-92-1 Cinnamoyl chloride 
• 140-10-3 (E)-3-phenylacrylic acid 
• 100-52-7 benzaldehyde 

Relevant academic research and scientific papers

UREA COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS

A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

UREA COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof. The present invention also relates to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. Further, the present invention relates to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for anti-apoptosis, preventing or treating a disease or disorder associated with apoptosis; especially useful for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

SAR, cardiac myocytes protection activity and 3D-QSAR studies of salubrinal and its potent derivatives

Salubrinal is a selective inhibitor of endoplasmic reticulum (ER) stress and affords remarkable protection to cardiomyocytes. By studying the structure-activity relationship (SAR) of salubrinal, it was found that modification of the quinoline ring terminus and thiourea unit could confer the compound PP1-24 with markedly enhanced cardioprotective activity (EC 50 2 = 0.741, r2 = 0.991).